TY - JOUR
T1 - Dose-Escalated Radiation Therapy for Pancreatic Cancer
T2 - A Simultaneous Integrated Boost Approach
AU - Koay, Eugene J.
AU - Hanania, Alexander N.
AU - Hall, William A.
AU - Taniguchi, Cullen M.
AU - Rebueno, Neal
AU - Myrehaug, Sten
AU - Aitken, Katharine L.
AU - Dawson, Laura A.
AU - Crane, Christopher H.
AU - Herman, Joseph M.
AU - Erickson, Beth
N1 - Funding Information:
Sources of support: We gratefully acknowledge support from the Andrew Sabin Family Fellowship, the Sheikh Ahmed Center for Pancreatic Cancer Research, institutional funds from the University of Texas MD Anderson Cancer Center, the Khalifa Foundation, equipment support by GE Healthcare and the Center of Advanced Biomedical Imaging, Philips Healthcare, and Cancer Center Support (Core) Grant CA016672 from the National Cancer Institute to MD Anderson. Dr Eugene Koay was supported by the National Institutes of Health (1R01CA218004-01A1, 1R01CA221971-01A1, U54CA210181-01, U54CA143837 and U01CA196403). Disclosures: Dr Koay reports grants from the National Institutes of Health, grants from Elekta, grants from Philips Healthcare, grants from GE, and grants from MD Anderson Cancer Center, during the conduct of the study; and personal fees from Taylor and Francis, LLC, outside the submitted work. Dr Hall reports other from Elekta, during the conduct of the study; and other from Siemens Healthineers, other from Accuray, and other from Manteia Medical Technologies, outside the submitted work. Dr Taniguchi reports other from Accuray, outside the submitted work. Dr Aitken reports personal fees and nonfinancial support from Elekta, outside the submitted work. Dr Myrehaug reports personal fees from Ipsen and grants and personal fees from Novartis, outside the submitted work. Dr Herman reports other from Augmenix, other from BTG, other from Oncosil, other from Medtronic, other from Sirtex, and other from Boston Scientific, outside the submitted work. Dr Erickson reports other from Elekta, during the conduct of the study; and other from Siemens Healthineers, other from Accuray, and other from Manteia Medical Technologies, outside the submitted work.
Funding Information:
Sources of support: We gratefully acknowledge support from the Andrew Sabin Family Fellowship, the Sheikh Ahmed Center for Pancreatic Cancer Research, institutional funds from the University of Texas MD Anderson Cancer Center , the Khalifa Foundation, equipment support by GE Healthcare and the Center of Advanced Biomedical Imaging, Philips Healthcare, and Cancer Center Support (Core) Grant CA016672 from the National Cancer Institute to MD Anderson. Dr Eugene Koay was supported by the National Institutes of Health ( 1R01CA218004-01A1 , 1R01CA221971-01A1 , U54CA210181-01 , U54CA143837 and U01CA196403 ).
Funding Information:
Disclosures: Dr Koay reports grants from the National Institutes of Health, grants from Elekta, grants from Philips Healthcare, grants from GE, and grants from MD Anderson Cancer Center, during the conduct of the study; and personal fees from Taylor and Francis, LLC, outside the submitted work. Dr Hall reports other from Elekta, during the conduct of the study; and other from Siemens Healthineers, other from Accuray, and other from Manteia Medical Technologies, outside the submitted work. Dr Taniguchi reports other from Accuray, outside the submitted work. Dr Aitken reports personal fees and nonfinancial support from Elekta, outside the submitted work. Dr Myrehaug reports personal fees from Ipsen and grants and personal fees from Novartis, outside the submitted work. Dr Herman reports other from Augmenix, other from BTG, other from Oncosil, other from Medtronic, other from Sirtex, and other from Boston Scientific, outside the submitted work. Dr Erickson reports other from Elekta, during the conduct of the study; and other from Siemens Healthineers, other from Accuray, and other from Manteia Medical Technologies, outside the submitted work.
Publisher Copyright:
© 2020 American Society for Radiation Oncology
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Purpose: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. Methods and Materials: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. Results: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. Conclusions: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.
AB - Purpose: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. Methods and Materials: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. Results: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. Conclusions: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.
UR - http://www.scopus.com/inward/record.url?scp=85082820455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082820455&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2020.01.012
DO - 10.1016/j.prro.2020.01.012
M3 - Article
C2 - 32061993
AN - SCOPUS:85082820455
SN - 1879-8500
VL - 10
SP - e495-e507
JO - Practical radiation oncology
JF - Practical radiation oncology
IS - 6
ER -